Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine hydrochloride capsules in acute schizophrenia
CTR20240938Phase 3Completed
- Sponsor
- Jingxin Pharmaceutical
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cariprazine in schizophrenia and bipolar I disorder (2 arms), sponsored by Jingxin Pharmaceutical. Primary endpoint: Change in PANSS total score from baseline to week 6. Started Mar 2024; status: completed.
02
Drugs
cariprazine
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on CTR20240938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240938.